Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inho Kim

Showing results (331-340 of 347) with videos related to

Pageof 35
Sort By:
Plos One|November 9, 2016
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeKoung Jin Suh, June-Won Cheong, Inho Kim, et al.
Annals of Hematology|February 25, 2010
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinibYoungil Koh, Inho Kim, Sung-Soo Yoon, et al.
Haematologica|July 3, 2025
Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemiaJae-Sook Ahn, Joo Heon Park, ChangSun Lee, et al.
Annals of Hematology|April 6, 2013
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemiaSang Min Lee, Won Sik Lee, Ho Jin Shin, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
American Journal of Hematology|October 19, 2012
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patientsInho Kim, Youngil Koh, Sung-Soo Yoon, et al.
Japanese Journal of Clinical Oncology|February 27, 2010
Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollmentHo-Jin Shin, Hyeoung-Joon Kim, Sang Kyun Sohn, et al.
Asia-Pacific Journal of Clinical Oncology|March 14, 2023
Radioimmunotherapy with <sup>131</sup> I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphomaYoon Jung Jang, Sang Moo Lim, Inki Lee, et al.
Leukemia Research|October 21, 2021
Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patientsHyunkyung Park, Inho Kim, Hyeong-Joon Kim, et al.
Pageof 35

Showing results (331-340 of 347) with videos related to

Sort By:
Pageof 35
Plos One|November 9, 2016
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeKoung Jin Suh, June-Won Cheong, Inho Kim, et al.
Annals of Hematology|February 25, 2010
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinibYoungil Koh, Inho Kim, Sung-Soo Yoon, et al.
Haematologica|July 3, 2025
Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemiaJae-Sook Ahn, Joo Heon Park, ChangSun Lee, et al.
Annals of Hematology|April 6, 2013
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemiaSang Min Lee, Won Sik Lee, Ho Jin Shin, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
American Journal of Hematology|October 19, 2012
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patientsInho Kim, Youngil Koh, Sung-Soo Yoon, et al.
Japanese Journal of Clinical Oncology|February 27, 2010
Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollmentHo-Jin Shin, Hyeoung-Joon Kim, Sang Kyun Sohn, et al.
Asia-Pacific Journal of Clinical Oncology|March 14, 2023
Radioimmunotherapy with <sup>131</sup> I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphomaYoon Jung Jang, Sang Moo Lim, Inki Lee, et al.
Leukemia Research|October 21, 2021
Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patientsHyunkyung Park, Inho Kim, Hyeong-Joon Kim, et al.
Pageof 35